NCT06475755 2024-06-26Neoadjuvant/Adjuvant Tislelizumab Combined With Anlotinib and Platinum Doublet Chemotherapy With Resectable NSCLCTang-Du HospitalPhase 2 Not yet recruiting178 enrolled
NCT04153734 2019-11-06EvolutionKobe Minimally Invasive Cancer CenterPhase 2 Not yet recruiting21 enrolled